ENXTPA:ABVXBiotechs
Is Abivax (ENXTPA:ABVX) Quietly Reframing Its Ulcerative Colitis Strategy Around Obefazimod’s Phase 3 Pathway?
Abivax has outlined its 2026 corporate outlook, emphasizing obefazimod’s potential in ulcerative colitis after the December 2025 ABTECT Phase 3 DSMB meeting reported no new safety signals and over 80% patient completion of the 44‑week maintenance trial.
An interesting takeaway is the company’s plan to leverage these Phase 3 data to pursue a US regulatory filing for obefazimod later in 2026, underscoring its ambitions in the ulcerative colitis treatment market.
Next, we’ll examine how the...